Lithium Carbonate ER

MARCH 01, 2004

Roxane Laboratories Inc (Columbus, Ohio) recently announced the approval of Lithium Carbonate Extended Release Tablets USP, 450 mg. This product is ABrated to GlaxoSmithKline?s Eskalith CR (lithium carbonate) 450 mg. Lithium Carbonate Extended Release Tablets are indicated for the treatment of manic episodes of manic?depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic?depressive patients with a history of mania. The tablets may produce a normalization of symptomatology within 1 to 3 weeks. For more information, visit www.roxane.com.



SHARE THIS SHARE THIS
0

Immunization Laws Around the Nation

Many areas of medicine that intersect with law and immunizations are associated with a very specific set of laws across the nation.  

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.